Since there is serious hope that AhR agonists may represent a new class of therapeutics in chronic inflammatory diseases, such as IBD, there is a need for reliable and standardised in-vivo models for preclinical selection and safety testing of numerous natural or synthetic AhR agonists. The gene discussed is AHR; the disease is inflammatory bowel disease.